Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
Author:
Publisher
Elsevier BV
Subject
Gastroenterology,Hepatology
Reference12 articles.
1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
3. NASH limits anti-tumour surveillance in immunotherapy-treated HCC
4. Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice
5. Emerging immunotherapy for HCC: A guide for hepatologists
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review;Clinical Journal of Gastroenterology;2024-08-20
2. Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts;Cancers;2024-06-28
3. Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy;The Oncologist;2024-06-27
4. MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options;Current Issues in Molecular Biology;2024-06-13
5. Treatment options for advanced hepatocellular carcinoma: the potential of biologics;Expert Opinion on Biological Therapy;2024-06-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3